Adjuvant Chemotherapy in the Treatment of Intraductal Papillary Mucinous Neoplasms of the Pancreas: Systematic Review and Meta‐Analysis
Open Access
- 20 September 2021
- journal article
- review article
- Published by Wiley in World Journal of Surgery
- Vol. 46 (1) , 223-234
Abstract
Background: The present systematic review aimed to compare survival outcomes of invasive intraductal papillary mucinous neoplasms (IIPMNs) treated with adjuvant chemotherapy versus surgery alone and to identify pathologic features that may predict survival benefit from adjuvant chemotherapy.Method: A systematic search of MEDLINE, PubMed, Scopus, and EMBASE was performed using the PRISMA framework. Studies comparing adjuvant chemotherapy and surgery alone for patients with IIPMNs were included. Primary endpoint was overall survival (OS). A narrative synthesis was performed to identify pathologic features that predicted survival benefits from adjuvant chemotherapy.Results: Eleven studies and 3393 patients with IIPMNs were included in the meta‐analysis. Adjuvant chemotherapy significantly reduced the risk of death in the overall cohort (HR 0.57, 95% CI 0.38–0.87,p = 0.009) and node‐positive patients (HR 0.29, 95% CI 0.13–0.64,p = 0.002). Weighted median survival difference between adjuvant chemotherapy and surgery alone in node‐positive patients was 11.6 months (95% CI 3.83–19.38,p = 0.003) favouring chemotherapy. Adjuvant chemotherapy had no impact on OS in node‐negative patients (HR 0.53, 95% CI 0.20–1.43,p = 0.209). High heterogeneity (I2 > 75%) was observed in pooled estimates of hazard ratios. Improved OS following adjuvant chemotherapy was reported for patients with stage III/IV disease, tumour size > 2 cm, node‐positive status, grade 3 tumour differentiation, positive margin status, tubular carcinoma subtype, and presence of perineural or lymphovascular invasion.Conclusion: Adjuvant chemotherapy was associated with improved OS in node‐positive IIPMNs. However, the findings were limited by marked heterogeneity. Future large multicentre prospective studies are needed to confirm these findings and explore additional predictors of improved OS to guide patient selection for adjuvant chemotherapy.Keywords
This publication has 49 references indexed in Scilit:
- Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trialBMJ, 2011
- Cystic Lesions of the Pancreas: Changes in the Presentation and Management of 1,424 Patients at a Single Institution over a 15-Year Time PeriodJournal of the American College of Surgeons, 2011
- Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II StudyJournal of Clinical Oncology, 2010
- Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapyHPB, 2010
- Invasive intraductal papillary mucinous neoplasm versus sporadic pancreatic adenocarcinomaCancer, 2010
- Histopathologic Basis for the Favorable Survival after Resection of Intraductal Papillary Mucinous Neoplasm-Associated Invasive Adenocarcinoma of the PancreasAnnals of Surgery, 2010
- Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated With Intraductal Papillary Mucinous Neoplasm of the PancreasInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic CancerNew England Journal of Medicine, 2004
- Measuring inconsistency in meta-analysesBMJ, 2003
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986